Bone metastases
Conditions
Interventions
We check the time course of calcium concentrations and risk factors for hypocalcemia in patients recieving denosumab. The follow-up period is three months after recieving densoumab.
Sponsors
Department of Orthopaedic Surgery, Showa University School of Medicine, Tokyo, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Ptienta are eligible for this study if they were (1)The patients who plan to use the denosumab for bone metastases. (2)The patient who approves participation to the clinical research.
Exclusion criteria
Exclusion criteria: Patients were excluded from the study if they had (1)contraindicate factors (2)hyperparathyroidism or under the pregnacy. (3)adjusted baseline serum calcium concentrations above or below the normal range in our laboratory.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of the risk factors associated with hypocalcemia induced by denosumab using bone turnover markers.We evaluate the correlations between bone turnover markers at baseline and change the value of the serum Ca from baseline to nadir in 3 months after administration of denosumab. | — |
Countries
Japan
Contacts
Public ContactKoji Ishikawa
Showa University School of Medicine Department of Orthopaedic Surgery
Outcome results
None listed